1文献来源Schuler M,Wu YL,Hirsh V,et al.First-lineAfatinib versus chemotherapy in patients with non-small cell lung cancer and common epidermal growthfactor receptor gene mutations and brain metastases[J].J Thorac Onco...1文献来源Schuler M,Wu YL,Hirsh V,et al.First-lineAfatinib versus chemotherapy in patients with non-small cell lung cancer and common epidermal growthfactor receptor gene mutations and brain metastases[J].J Thorac Oncol,2016,11（3）：380-390.2证据水平2a。3背景EGFR阳性的非小细胞肺癌（non-small celllung cancer,NSCLC）出现脑转移的概率高达44%~63%,但目前极少有针对此类患者的前瞻性临床研究。展开更多
1文献来源Wu YL,Zhou CC,Hu CP,et al.Afatinib versus Cisplatin plus Gemcitabine for first-linetreatment of Asian patients with advanced non-smallcell lung cancer harbouring EGFR mutations（LUXLung 6）：An open-label,ran...1文献来源Wu YL,Zhou CC,Hu CP,et al.Afatinib versus Cisplatin plus Gemcitabine for first-linetreatment of Asian patients with advanced non-smallcell lung cancer harbouring EGFR mutations（LUXLung 6）：An open-label,randomised phase 3 trial[J].Lancet Oncol,2014,15（2）：213-222.2证据水平1b。3背景表皮生长因子受体（epidermal growth factor receptor,EGFR）酪氨酸激酶抑制剂（tyrosine kinase inhibitor,TKI）与化疗相比,能够明显延长EGFR突变晚期非小细胞肺癌（non-small cell lung cancer,NSCLC）患者的生存期,目前已开展许多相关临床试验,展开更多
文摘建立了同时定量测定大鼠血浆中阿帕替尼和紫杉醇的超高效液相色谱-串联质谱(UPLC-MS/MS)方法,并应用于药动学研究。血浆样品经固相萃取(SPE)处理。色谱柱为Agilent Zorbax Eclipse Plus C18柱(100 mm×2.1 mm,1.8μm),流动相为乙腈-0.1%甲酸溶液,体积流量0.4 m L/min,柱温40℃,进样量为3μL。质谱采用电喷雾正离子源模式(ESI+),多反应监测模式(MRM)进行定量测定。阿帕替尼和紫杉醇在0.5~1 500μg/L范围内均呈良好的线性关系(r2≥0.998),最低定量下限(LLOQ)均为0.5μg/L,日内、日间精密度RSD≤8.4%,准确度为92.5%~107.1%,提取回收率为86.2%~95.1%,基质效应(86.6%~108.6%)不影响待测物血药浓度的测定。经方法学验证,该法快速灵敏,可同时对阿帕替尼和紫杉醇进行血药浓度监测,为临床联合用药研究提供了重要的分析手段。
文摘1文献来源Schuler M,Wu YL,Hirsh V,et al.First-lineAfatinib versus chemotherapy in patients with non-small cell lung cancer and common epidermal growthfactor receptor gene mutations and brain metastases[J].J Thorac Oncol,2016,11（3）：380-390.2证据水平2a。3背景EGFR阳性的非小细胞肺癌（non-small celllung cancer,NSCLC）出现脑转移的概率高达44%~63%,但目前极少有针对此类患者的前瞻性临床研究。
